



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/813,760

03/31/2004

Joel E. Bernstein

41959-102739

5267

23644 7590 12/19/2008  
BARNES & THORNBURG LLP  
P.O. BOX 2786  
CHICAGO, IL 60690-2786

EXAMINER

KWON, BRIAN YONG S

ART UNIT

PAPER NUMBER

1614

NOTIFICATION DATE

DELIVERY MODE

12/19/2008

ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patent-ch@btlaw.com

<b>Office Action Summary</b>	<b>Application No.</b> 10/813,760	<b>Applicant(s)</b> BERNSTEIN, JOEL E.	
	<b>Examiner</b> Brian-Yong S. Kwon	<b>Art Unit</b> 1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 07/01/2008.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-3, 5-9 and 11-37 is/are pending in the application.
- 4a) Of the above claim(s) 16-37 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-3, 5-9 and 11-15 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)            | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>10/20/08</u> .  | 6) <input type="checkbox"/> Other: _____                          |

***DETAILED ACTION***

***Status of Application***

1. Acknowledgement is made of applicant's Amendment/Remarks filed on 07/01/2008. By the amendment, claims 1 and 30 have been amended and claim 4 has been cancelled. Claims 1-3, 5-9 and 11-15 are currently pending for prosecution on the merits.
2. It is noted that the examiner's previous indication of allowable claims (claims 13-15), in the Notice of Allowability mailed 02/26/03, has been withdrawn upon reconsideration of the claims.
3. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set of actions being applied to the instant application.

***Information Disclosure Statement***

4. Enclosed is an initialed copy of PTO 1449 which has been considered for your records, Application No. 10/813/760.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1614

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 1-3, 5-9 and 11-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kroger et al. (Gen. Pharmac., Vol. 28, No. 2, pp. 257-263, 1997), and further in view of Ogata et al. (USP 5478815) and Murdock (USP 4526788).

Kroger teaches use of combination of nicotinamide (12.5mg/kg IP or from 25 mg/kg to 100mg/kg IP) and methionine (12.5mg/kg IP or from 25 mg/kg to 100mg/kg IP) in decreasing hepatotoxicity induced by the hepatotoxic compound such as 500mg/kg of acetaminophen (abstract; Figure 2; Results; Discussion). Kroger teaches that the combination of l-methionine and nicotinamide even at lower dose of 12.5mg/kg IP each synergistically results in complete protection from acetaminophen-induced release of GOT and GPT.

Art Unit: 1614

Ogata is being provided as a supplemental reference to demonstrate the routine knowledge (in pharmaceutical art) in using intraperitoneal injection as experimental animal testing for the administration of systemic or oral drugs (Examples; column 2, lines 28-31).

Murdock is being provided as a supplemental reference to demonstrate the routine knowledge (in pharmaceutical art) in calculating human dosage based on the interrelationship of dosages for animals of various sizes and species and humans described by Freireich, E. J., et. al., Rep., 50, No. 4, 219-244, May 1966 (column 5, lines 45-51).

Kroger differs from the claimed invention in (i) the preparation of a composition comprising acetaminophen, nicotinamide and methionine in the specific amounts, namely about 80-1000 mg dose of acetaminophen, about 5 mg to about 500 mg dose of methionine and about 10 mg to about 500 mg dose of nicotinamide, per standard dose, (ii) the preparation of said composition in various dosage forms, namely oral or sterile solutions or suspensions form, more preferably tablets, capsules, caplets, intradermal, subcutaneous, intramuscular, intravenous or intrathecal.

One having ordinary skill in the art would have expected as taught by Kroger that the combination of methionine and nicotinamide would provide protection from acetaminophen-induced liver damage and motivated to make such modification to prepare known hepatotoxic drug such as acetaminophen with nicotinamide and methionine combination in various pharmaceutical dosage forms to accommodate patient's preference and needs where the compliance could be improved with effective and well tolerated dosage form. One having ordinary skill in the art would have expected at the time of the invention was made that the results from Kroger could apply to the development of other modes of administration, for

Art Unit: 1614

example systemic and/or oral administration. As discussed in preceding comments, it was known at the time of the invention was made that intraperitoneal injection is used as experimental animal testing for the administration of systemic or oral drugs (due to ease of administration compared with other parenteral methods in animal study). Thus, one having ordinary skill in the art has bases for perceiving Kroger's study as constituting recognized animal study with clear relevance to utility systemic and/or oral administration in humans or animals.

One would have been motivated to combine these references and make the modification because they are drawn to same technical fields (constituted with same ingredients and share common utilities), and pertinent to the problem which applicant concerns about. MPEP 2141.01(a).

Determination of the specific dosage amounts of each ingredient in said composition and/or the specific delivery dosage forms, those of ordinary skill in the art would have been readily optimized effective dosages amounts and/or dosage forms as determined by good medical practice and the clinical condition of the individual patient. Regardless of the manner of administration, the specific dose would have been calculated according to body weight, body surface area or organ size. Determination of the appropriate dosage amounts or dosage forms for treatment involving each of the above mentioned formulations would have been routinely made by those of ordinary skill in the art and is within the ability of tasks routinely performed by them without undue experimentation, especially in light of the dosage information disclosed in the prior art references. For example, the referenced 12.5 mg/kg dose of methionine or nicotinamide in mouse is equivalent to 1.04 mg/kg in human (base on Freireich EJ. Et al., 1966 conversion

factor) which falls within the instantly claimed dosage range of either methionine or nicotinamide. Therefore, the references in combination make obvious the instant invention.

Generally, differences in dosage amounts or dosage forms will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such dosage amounts or dosage forms is critical. Where the general conditions of a claim are disclosed in the prior art, it not inventive to discover the optimum or workable dosage amounts or dosage forms by routine experimentation.

### Conclusion

6. No Claim is allowed.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached on (571) 272-0718. The fax number for this Group is (571) 273-8300.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system,

Art Unit: 1614

see <http://pair-direct.uspto.gov> Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

/Brian-Yong S Kwon/

Primary Examiner, Art Unit 1614